

The reviewer suggested inclusion of the below published papers, however these papers are not relevant to our systematic review.

Mannucci E, Naletto L, Vaccaro G, Silverii A, Dicembrini I, Pintaudi B, Monami M. Efficacy and safety of glucose-lowering agents in patients with type 2 diabetes: A network meta-analysis of randomized, active comparator-controlled trials. *Nutr Metab Cardiovasc Dis*. 2021 Apr 9;31(4):1027-1034. doi: 10.1016/j.numecd.2020.12.030. Epub 2021 Jan 11. PMID: 33618919.

- This article does not meet the inclusion criteria of the systematic review and irrelevant to the review. Out study aimed to compare the bA1c reduction of iGlarLixi versus IDegLira and does not look at GLP-1 agonists in non-fixed ratio combinations.

Rayner CK, Wu T, Aroda VR, Whittington C, Kanters S, Guyot P, Shaunik A, Horowitz M. Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis.

- This article does not meet the inclusion criteria of the systematic review and irrelevant to the review

Diabetes Obes Metab. 2021 Jan;23(1):136-146 -Gentilella R, Pechtner V, Corcos A, Consoli A. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? *Diabetes Metab Res Rev*. 2019 Jan;35(1):e3070. 4.

- This is a narrative review and does not meet inclusion criteria for the study